Poor R-wave progression as a predictor of sudden cardiac death in the general population and subjects with coronary artery disease
Schröder, Linda C.; Holkeri, Arttu; Eranti, Antti; Haukilahti, M. Anette E.; Kerola, Tuomas; Kenttä, Tuomas V.; Noponen, Kai; Seppänen, Tapio; Rissanen, Harri; Heliövaara, Markku; Knekt, Paul; Junttila, M. Juhani; Huikuri, Heikki V.; Aro, Aapo L. (2022-02-15)
Schröder, L. C., Holkeri, A., Eranti, A., Haukilahti, M. A. E., Kerola, T., Kenttä, T. V., Noponen, K., Seppänen, T., Rissanen, H., Heliövaara, M., Knekt, P., Junttila, M. J., Huikuri, H. V., & Aro, A. L. (2022). Poor R-wave progression as a predictor of sudden cardiac death in the general population and subjects with coronary artery disease. Heart Rhythm, 19(6), 952–959. https://doi.org/10.1016/j.hrthm.2022.02.010
© 2022 Heart Rhythm Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe2023060552465
Tiivistelmä
Abstract
Background: Poor R-wave progression (PRWP) is a common clinical finding on the standard 12-lead electrocardiogram (ECG), but its prognostic significance is unclear.
Objective: The purpose of this study was to examine the prognosis associated with PRWP in terms of sudden cardiac death (SCD), cardiac death, and all-cause mortality in general population subjects with and without coronary artery disease (CAD).
Methods: Data and 12-lead ECGs were collected from a Finnish general population health examination survey conducted during 1978–1980 with follow-up until 2011. The study population consisted of 6854 subjects. Main end points were SCD, cardiac death, and all-cause mortality. PRWP was defined as R-wave amplitude ≤ 0.3 mV in lead V₃ and R-wave amplitude in lead V₂ ≤ R-wave amplitude in lead V₃.
Results: PRWP occurred in 213 subjects (3.1%). During the follow-up period of 24.3 ± 10.4 years, 3723 subjects (54.3%) died. PRWP was associated with older age, higher prevalence of heart failure and CAD, and β-blocker medication. In multivariate analyses, PRWP was associated with SCD (hazard ratio [HR] 2.13; 95% confidence interval [CI] 1.34–3.39), cardiac death (HR 1.75; 95% CI 1.35–2.15), and all-cause mortality (HR 1.29; 95% CI 1.08–1.54). In the subgroup with CAD, PRWP had a stronger association with cardiac mortality (HR 1.71; 95% CI 1.19–2.46) than in the subgroup without CAD, while the association with SCD was significant only in the subgroup with CAD (HR 2.62; 95% CI 1.38–4.98).
Conclusions: PRWP was associated with adverse prognosis in the general population and with SCD in subjects with CAD.
Kokoelmat
- Avoin saatavuus [37125]